CombiMatrix Needs to Raise Funds as Q4 Revenues Fall 37 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix reported after the close of the market on Wednesday that its fourth-quarter revenues decreased 37 percent as revenue from government contracts and products declined year over year.

In addition, the firm said that it would need to raise additional funds, as its $9.1 million in cash, cash equivalents, and available-for-sale investments as of the end of 2008 will carry the firm only until September.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment.